BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17323509)

  • 1. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
    Gupta SK
    AIDS Read; 2009; 19(6):246. PubMed ID: 19642244
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
    Atta MG; Fine DM
    AIDS Read; 2009 Mar; 19(3):118-9. PubMed ID: 19334329
    [No Abstract]   [Full Text] [Related]  

  • 4. Tenofovir and changes in renal function.
    Gupta SK
    Clin Infect Dis; 2005 Aug; 41(4):570-1; author reply 571. PubMed ID: 16028175
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenofovir-induced nephrotoxicity: myths and facts.
    Gupta A; Bugeja A; Kirpalani D
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):148-9. PubMed ID: 22237241
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
    Psevdos G; Gonzalez E; Sharp V
    AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypokalemia in HIV patients on tenofovir.
    Cirino CM; Kan VL
    AIDS; 2006 Aug; 20(12):1671-3. PubMed ID: 16868451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal safety of tenofovir disoproxil fumarate.
    Sax PE; Gallant JE; Klotman PE
    AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
    AIDS Patient Care STDS; 2009 Aug; 23(8):680-1. PubMed ID: 19694040
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H
    AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
    Szczech LA
    J Infect Dis; 2008 Jan; 197(1):7-9. PubMed ID: 18171278
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
    Gracey D; Post J; MacLeod C; McKenzie P
    Nephrology (Carlton); 2011 May; 16(4):453-5. PubMed ID: 21518120
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
    Winston J; Shepp DH
    HIV Med; 2006 Oct; 7(7):484-5. PubMed ID: 16925736
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment: tenofovir nephrotoxicity--vigilance required.
    Fine DM
    AIDS Read; 2005 Jul; 15(7):362-3. PubMed ID: 16044578
    [No Abstract]   [Full Text] [Related]  

  • 16. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 18. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
    Gallant JE; Parish MA; Keruly JC; Moore RD
    Clin Infect Dis; 2005 Apr; 40(8):1194-8. PubMed ID: 15791522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
    Kakuda TN; Anderson PL; Becker SL
    AIDS; 2004 Dec; 18(18):2442-4. PubMed ID: 15622326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.